Sex differences in protective effect of recombinant human erythropoietin against cisplatin-induced nephrotoxicity in rats

Iranian Journal of Kidney Diseases

Volumn 7, Issue 5, 2013, Pages 383-389

  Eshraghi Jazi, Fatemeh ^a   Nematbakhsh, Mehdi ^a,b   Pezeshki, Zahra ^a   Nasri, Hamid ^a,b   Talebi, Ardeshir ^a   Safari, Tahereh ^a   Mansouri, Azam ^a   Mazaheri, Safoora ^a   Ashrafi, Farzaneh ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cisplatin; Erythropoietin; Kidney failure; Rats; Sex

Indexed keywords

CISPLATIN; CREATININE; MALONALDEHYDE; NITRITE; NITROGEN; RECOMBINANT ERYTHROPOIETIN; SODIUM CHLORIDE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; KIDNEY INJURY; KIDNEY MASS; MALE; NEPHROTOXICITY; NONHUMAN; RAT; RENAL PROTECTION; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION;

ACUTE KIDNEY INJURY; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD UREA NITROGEN; BODY WEIGHT; CISPLATIN; CREATININE; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; FEMALE; KIDNEY; MALE; MALONDIALDEHYDE; NITRITES; ORGAN SIZE; RANDOM ALLOCATION; RATS; RATS, WISTAR; SEX CHARACTERISTICS; SEX FACTORS;

EID: 84884765307     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Moore E, Bellomo R. Erythropoietin (EPO) in acute kidney injury. Ann Intensive Care. 2011;1:3.
2. Yasari F, Nafar M, Alipour Abdei B, et al. Effect of erythropoietin on kidney allograft survival: early use after transplantation. Iran J Kidney Dis. 2012;6:44-8.
3. Nemati E, Abbaszadeh S. Re: effect of erythropoietin on kidney allograft survival: early use after transplantation. Iran J Kidney Dis. 2012;6:227.
4. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004;19:348-355.
5. Ravindra P, Bhiwgade DA, Kulkarni S, Rataboli PV, Dhume C Y. Cisplatin induced histological changes in renal tissue of rat. J Cell Animal Biol. 2010;4:108-111.
6. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334:115-124.
7. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci USA. 2002;99:4592-4595.
8. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol. 2008;61:903-909.
9. Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis. 1986;8:368-379.
10. Leonard BJ, Eccleston E, Jones D, Todd P, Walpole A. Antileukaemic and nephrotoxic properties of platinum compounds. Nature. 1971;234:43-45.
11. Nematbakhsh M, Ashrafi F, Safari T, et al. Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats. J Nephrol. 2012;25:410-417.
12. Atasayar S, Gurer-Orhan H, Orhan H, Gurel B, Girgin G, Ozgunes H. Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats. Exp Toxicol Pathol. 2009;61:23-32.
13. Maliakel DM, Kagiya TV, Nair CK. Prevention of cisplatin-induced nephrotoxicity by glucosides of ascorbic acid and alpha-tocopherol. Exp Toxicol Pathol. 2008;60:521-527.
14. Ashrafi F, Nematbakhsh M, Safari T, et al. A combination of vitamin C and losartan for cisplatin-induced nephrotoxicity in rats. Iran J Kidney Dis. 2012;6:361-365.
15. Hadjzadeh MA, Keshavarzi Z, Tabatabaee Yazdi SA, Ghasem Shirazi M, Rajaei Z, Khajavi Rad A. Effect of alcoholic extract of Nigella sativa on cisplatin-induced toxicity in rat. Iran J Kidney Dis. 2012;6:99-104.
16. Yalcin S, Muftuoglu S, Cetin E, et al. Protection against cisplatin-induced nephrotoxicity by recombinant human erythropoietin. Med Oncol. 2003;20:169-174.
17. Lee DW, Kwak IS, Lee SB, et al. Post-treatment effects of erythropoietin and nordihydroguaiaretic acid on recovery from cisplatin-induced acute renal failure in the rat. J Korean Med Sci. 2009;24 Suppl:S170-S175.
18. Sabolic I, Asif AR, Budach WE, Wanke C, Bahn A, Burckhardt G. Gender differences in kidney function. Pflugers Arch. 2007;455:397-429.
19. Safari T, Nematbakhsh M, Hilliard LM, Evans RG, Denton KM. Sex differences in the renal vascular response to angiotensin II involves the Mas receptor. Acta Physiol (Oxf). 2012;206:150-6.
20. Hilliard LM, Nematbakhsh M, Kett MM, et al. Gender differences in pressure-natriuresis and renal autoregulation: role of the Angiotensin type 2 receptor. Hypertension. 2011;57:275-282.
21. Xu R, Zhang LX, Zhang PH, Wang F, Zuo L, Wang HY. Gender differences in age-related decline in glomerular filtration rates in healthy people and chronic kidney disease patients. BMC Nephrol. 2010;11:20.
22. Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol. 2000;11:319-329.
23. Tucker WE, Jr., Janssen FW, Agersborg HP, Jr., Young EM, Ruelius HW. Sex- and species-related nephropathy of 6-(1-aminocyclohexanecarboxamido)penicillanic acid (cyclacillin) and its relationship to the metabolic disposition of the drug. Toxicol Appl Pharmacol. 1974;29:1-18.
24. Pohl LR, George JW, Satoh H. Strain and sex differences in chloroform-induced nephrotoxicity. Different rates of metabolism of chloroform to phosgene by the mouse kidney. Drug Metab Dispos. 1984;12:304-308.
25. Prokai A, Fekete A, Banki NF, et al. Renoprotective effect of erythropoietin in rats subjected to ischemia/reperfusion injury: gender differences. Surgery. 2011;150:39-47.
26. Nematbakhsh M, Talebi A, Nasri H, et al. Some evidence for sex-based differences in cisplatin-induced nephrotoxicity in rats. Clin Exp Med Lett. 2012;53:29-31.
27. Eshraghi-Jazi F, Nematbakhsh M, Nasri H, et al. The protective role of endogenous nitric oxide donor (L-arginine) in cisplatin-induced nephrotoxicity: Gender related differences in rat model. J Res Med Sci. 2011;16:1389-1396.
28. Haghighi M, Nematbakhsh M, Talebi A, et al. The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: gender-related differences. Ren Fail. 2012;34:1046-1051.
29. Stakisaitis D, Dudeniene G, Jankunas RJ, Grazeliene G, Didziapetriene J, Pundziene B. Cisplatin increases urinary sodium excretion in rats: gender-related differences. Medicina (Kaunas). 2010;46:45-50.
30. Bagnis C, Beaufils H, Jacquiaud C, et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant. 2001;16:932-938.
31. Mohamed HE, El-Swefy SE, Mohamed RH, Ghanim AM. Effect of erythropoietin therapy on the progression of cisplatin induced renal injury in rats. Exp Toxicol Pathol. 2013;65:197-203.
32. Rjiba-Touati K, Ayed-Boussema I, Bouaziz C, et al. Protective effect of erythropoietin against cisplatin-induced nephrotoxicity in rats: antigenotoxic and antiapoptotic effect. Drug Chem Toxicol. 2012;35:89-95.
33. Rjiba-Touati K, Boussema IA, Belarbia A, Achour A, Bacha H. Protective effect of recombinant human erythropoietin against cisplatin-induced oxidative stress and nephrotoxicity in rat kidney. Int J Toxicol. 2011;30:510-517.
34. Ohno T, Kato S, Wakatsuki M, et al. Incidence and temporal pattern of anorexia, diarrhea, weight loss, and leukopenia in patients with cervical cancer treated with concurrent radiation therapy and weekly cisplatin: comparison with radiation therapy alone. Gynecol Oncol. 2006;103:94-99.
35. Endo Y, Kanbayashi H. Modified rice bran beneficial for weight loss of mice as a major and acute adverse effect of Cisplatin. Pharmacol Toxicol. 2003;92:300-303.
36. Ammer U, Natochin Y, David C, Rumrich G, Ullrich KJ. Cisplatin nephrotoxicity: site of functional disturbance and correlation to loss of body weight. Ren Physiol Biochem. 1993;16:131-145.
37. Atessahin A, Ceribasi AO, Yuce A, Bulmus O, Cikim G. Role of ellagic acid against cisplatin-induced nephrotoxicity and oxidative stress in rats. Basic Clin Pharmacol Toxicol. 2007;100:121-126.
38. Cetin H, Olgar S, Oktem F, et al. Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model. Clin Exp Pharmacol Physiol. 2007;34:1181-1185.
39. Solaroglu I, Solaroglu A, Kaptanoglu E, et al. Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brain. Childs Nerv Syst. 2003;19:19-22.
40. Kumral A, Baskin H, Gokmen N, et al. Selective inhibition of nitric oxide in hypoxic-ischemic brain model in newborn rats: is it an explanation for the protective role of erythropoietin? Biol Neonate. 2004;85:51-54.
41. Pallet N, Bouvier N, Legendre C, et al. Antiapoptotic properties of recombinant human erythropoietin protects against tubular cyclosporine toxicity. Pharmacol Res. 2010;61:71-75.
42. Sharples EJ, Yaqoob MM. Erythropoietin in experimental acute renal failure. Nephron Exp Nephrol. 2006;104:e83-e88.
43. Goodnough LT, Price TH, Parvin CA. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender. J Lab Clin Med. 1995;126:57-64.
44. Halbesma N, Brantsma AH, Bakker SJ, et al. Gender differences in predictors of the decline of renal function in the general population. Kidney Int. 2008;74:505-512.
45. Kang AK, Miller JA. Effects of gender on the renin-angiotensin system, blood pressure, and renal function. Curr Hypertens Rep. 2002;4:143-151.
46. Williams PD, Bennett DB, Gleason CR, Hottendorf GH. Correlation between renal membrane binding and nephrotoxicity of aminoglycosides. Antimicrob Agents Chemother. 1987;31:570-574.
47. Pequignot JM, Spielvogel H, Caceres E, et al. Influence of gender and endogenous sex steroids on catecholaminergic structures involved in physiological adaptation to hypoxia. Pflugers Arch. 1997;433:580-586.